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A tumor suppressor role for miR-203 in RAS-dependent prostate cancer metastasis has been described recently 
by our group. We have explored the regulatory mechanisms by which miR-203 is being regulated through 
EGFR signaling. We investigated the molecular mechanism of metastasis and identified novel roles of genes that 
interact with miR-203 downstream of activated Ras. We showed an amplifying regulatory loop involving the 
direct interaction of miR-203 with the EGFR ligands, AREG, EREG, and TGFA 3’UTR. Using clinical 
specimens and database analysis, our data suggested that decreasing miR-203 and increasing EGFR ligands, 
AREG, EREG, and TGFA expressions are correlated with prostate cancer progression. Since tyrosine kinase 
inhibitors (TKIs) have been shown to inhibit tyrosine phosphorylation of EGFR in a dose-dependent manner, we 
examined a role for miR-203 in TKIs-induced apoptosis in RAS-activated prostate cancer. We investigated the 
mechanisms by which miR-203 overexpression contributes to TKIs-resistant RAS-activated prostate cancer cells 
apoptosis. We have shown indications for candidate miR-203 targets that are either influenced by anti-apoptotic 
proteins (e.g. API5, BIRC2, and TRIAP1) or positively influenced by a novel NF-κB-inducible oncogenic 
molecule, TNFAIP8. These observations suggest that the latter category may be synergistically affected by the 
regulatory loop of miR-203 depletion and anti-apoptotic proteins overexpression. Our results provided evidence 
showing a role of miR-203 in regulating the expression of EGFR signaling genes in response to TKIs-resistance 
during prostate cancer progression. 
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Prostate cancer (PC) is the most commonly diagnosed 
cancer and the second most common cause of death among 
men in the United States 
[1]
. PC is usually
androgen-dependent and thus, androgen deprivation therapy 
has been the standard treatment of PC for a long time. 
However, after a few years of treatment, PC may become 
resistant to such treatment, rendering it highly incurable due 
to the high recurrence rate. Furthermore, the fatality of PC 
lies in its drug resistance and vigorous ability to metastasize 
to distant organs such as bones, lymph nodes, liver, lungs 
and the brain 
[2]
. It is imperative to understand the various
mechanisms responsible for the progression of PC in order to 
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devise more effective targeted therapies. 
Prostate cancer has been mostly linked to the epidermal 
growth factor receptor (EGFR) dysfunction, which upon 
activation induces cell survival, proliferation, invasion, 
metastasis, and thus, drug resistance 
[3, 4]
. Furthermore, PC 
drug resistance could stem out from downstream EGFR 
genetic mutations, such as the KRAS, which in turn could 
activate the EGFR in an autocrine manner 
[5, 6]
. 
Current research is focusing a lot on the domain of 
microRNAs, which has been found to influence many 
physiological and pathological conditions. The exact 
mechanism by which microRNAs are able to initiate a 
pathological state is still unclear, but specific microRNAs 
have been studied and their presence or absence has been 
associated with certain types of cancers. Our microRNA of 
interest, miR-203, has been proposed to have 
tumor-suppressive functions in different types of cancers, 
including lung, breast and skin cancer 
[7-9]
. Moreover, a 
down-regulation of miR-203 has been specifically implicated 
in bone metastatic PC, whether it be in cell lines or clinical 
specimens 
[10]
. Yet, the way by which miR-203 modulates 
EGFR signaling is still unclear. 
Therefore, we aimed to study miR- 203 expression in PC 
cell lines and human specimens, and its effect in suppressing 
bone metastasis and inducing apoptosis in tyrosine kinase 
inhibitors (TKI)-resistant Ras-activated PC cells in which 
miR-203 is down-regulated by EGFR signaling
[11]
. We found 
that miR-203 directly targets the 3’UTR of the mRNAs of 
EGFR ligands (EREG and TGFA) and anti-apoptotic proteins 
(API5, BIRC2, and TRIAP1). In addition, inhibiting miR-203 
induced both cell invasion and TKI resistance in PC cells, 
meaning that miR-203 has a prominent role in the EGFR 
network. We conclude that PC tumors with down-regulated 
expression of miR-203 have an increase in EGFR ligands 
(EREG and TGFA) and anti-apoptotic proteins (API5, 
BIRC2, and TRIAP1) expression, leading to PC bone 
metastasis and TKIs resistance. 
RAS-dependent signaling has been found to contribute to 
the aggressiveness, metastasis, tumor grade and prognosis of 
PC 
[12, 13]
, where DU145, a human non-metastatic prostate 
cancer cell line, has been shown to rapidly form larger 
metastatic lesions when having a RasG37 mutation 
[14]
. To 
make sure if there was any association between miR-203 and 
Ras signaling, we studied the expression of miR-203 and its 
associated mRNAs in a publicly available data set of 99 
primary tumors and 13 distant metastasis tissue specimens 
collected and analyzed at Memorial Sloan-Kettering Cancer 
Center 
[15]
. According to an analysis of summed z-scores, we 
found that miR-203 was down-regulated in metastatic 
specimens and samples with altered KRAS signaling, while 
in samples with high expression of miR-203, EGFR pathway 
gene signatures were down-regulated. Furthermore, we 
examined the expression of miR-203 in DU145 cells 
harboring different Ras mutations and found that it was 
mostly reduced in the bone-derived RasB1 clone. Moreover, 
we found an increased p-EGFR and p-ERK1/2 expression in 
cells with a Ras mutation, which was reversed when we 
forced the overexpression of miR-203 precursor in RasB1 
and LNCap cells.  
We further assessed the effect of overexpressing miR-203 
in Ras-mutated PC cells lines. We found a reduced invasion 
and bone metastasis potential in RasB1 and reduced cell 
growth and invasion in DU145 cell lines. Furthermore, we 
found that the mRNA levels of the EGFR ligands, AREG, 
EREG, and TGFA, were up-regulated in RasB1, indicating 
increased autocrine activation. Upon treatment with EGF and 
EGFR inhibitor (CI1033), the EGFR ligands were increased 
and decreased, respectively. On the other hand, miR-203 was 
increased upon treatment with CI1033 and decreased upon 
EGF treatment. We proposed the presence of a miR-203 
binding site on the above-mentioned EGFR ligands, since 
their expression is decreased in the presence of miR-203 and 
decreased luciferase activities were detected upon 
co-transfection with miR-203 precursor by reporter assay in 
RasB1 cells. Moreover, this effect was ameliorated and 
3’UTR activity of the ligands was induced in DU145 
following miR-203 inhibition.  
Next, we analyzed 25 independent prostate tumors 
collected from Wang Fang Hospital, Taipei Medical 
University, Taiwan, to check if our in vitro findings coincide 
with human specimens. Upon dividing the specimens into 
two groups of high or low expression of EREG and TGFA, 
we found that there was an inverse correlation between 
miR-203 and EREG and TGFA expression, but not AREG. 
Incidentally, specimens with high AREG, EREG and TGFA 
expression were metastatic tumors and had higher KRAS 
oncogenic response gene signatures. 
We then sought to uncover the role of miR-203 in 
mediating apoptosis in TKI-resistant Ras-activated PC cells. 
We found that RasB1 cells lose their resistance to death via 
EGFR inhibitors when transfected with miR-203 and DU145 
cells gain resistance via activating the EGFR pathway when 
transfected with anti-miR-203. Furthermore, miR-203 
over-expression was associated with a TKI-induced increase 
in caspase-3/7 in RasB1 cells, which was not the case in 
DU145 cells. The next step was an in vivo experiment where 
overexpressing miR-203 in RasB1 cells led to an increased 
sensitivity to TKI-induced apoptosis and a decrease in tumor 
growth in nude mice, following 3 weeks of CI1033 
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treatment. This means that miR-203 may control various 
apoptotic or anti-apoptotic genes related to the EGFR 
signaling pathway. 
To validate the ability of miR-203 to modulate 
anti-apoptotic pathways, we studied the effect of EGF on 
RasB1 cells and found that it increased the mRNA 
expression of the anti-apoptotic genes API5, BIRC2and 
TRIAP1, whereas miR-203 precursor decreased them. 
Furthermore, the presence of anti-miR-203 in DU145 
decreased the mRNA expression of API5, BIRC2 and 
TRIAP1. In addition to that, miR-203 was found to regulate 
the NF-kB-inducible, oncogenic TNFAIP8 molecule.  
All in all, our study suggests that miR-203 is an important 
mediator in the progression and aggressiveness of prostate 
cancer. It has been shown to modulate downstream genes of 
the EGFR signaling pathway (EREG and TGFA), apoptotic 
genes (API5, BIRC2 and TIAP1) and other genes such as 
TNFAIP8. This adds to the multitude of studies that are 
delving deeper into the world of microRNAs and discovering 
that these tiny genetic pieces are capable of directing many 
physiological and pathological states. This is why we 
continued our search for more microRNAs involved in 
prostate cancer production and augmentation. 
Our focus remained on alterations in the Ras signaling 
pathway. According to the literature, it has been shown that 
activation of the Ras pathway in PC is correlated with 
alterations in other pathways such as the mitogen-activated 
protein kinase (MAPK), phosphatidylinositol 3-kinase 
(PI3K)/AKT cascades 
[16, 17]
, and WNT signaling 
[18]
. 
Interestingly, aberrant WNT signaling may develop through 
accumulated β-catenin that associates with members of the 
T-cell factor (TCF) and lymphoid enhancer factor (LEF) in 
the nucleus 
[19]





 and cyclin D1 genes 
[22]
. It is 
hypothesized that aggressive PC is the result of activated 
WNT signaling via the loss of regulation of transcription 
factor 7 (TCF7) expression and β-catenin accumulation. Of 
interest, microRNAs have been found to regulate the 
WNT-β-catenin pathway by binding to the 3’UTR region 
[23]
. 
Specifically, miR-34a has been implicated in malignant PC 
and has shown anti-proliferative and apoptotic effects 
[24, 25]
. 
Thus, we are currently seeking to understand the tumor 
suppressive role of miR-34a in PC in modulating the 
canonical WNT pathway. 
In short, out results reveal that reduced miR-34a 
expression is accompanied with activated WNT signaling 
genes, specifically in PC that metastasizes to the bone (cell 
lines and human specimens). On the other hand, increasing 
miR-34a expression reduces TCF7 expression, bone 
metastasis and proliferation and increases the anti-apoptotic 
BIRC5 gene expression in cancer cell lines. For this reason, 
we postulate that miR-34a deficiency is required for bone 
metastasis and the anti-apoptotic ability of Ras-mutated PC 
cells in which the WNT/TCF7 pathway and BIRC5 are 
activated. 
With more research, we are beginning to understand the 
intricate mechanisms underlying the production and 
progression of cancerous cells, at the level of microRNAs. 
We have shown that bone metastasis and TKI resistance in 
prostate cancer could be mediated via the loss of miR-203, 
which in turn leads to EGFR signaling dysregulation. A 
further study also led us to believe that the aggressiveness of 
prostate cancer could also be mediated through another 
microRNA, the miR-34a, where its loss would lead to the 
activation of the WNT/TCF7 signaling pathway. These 
microRNAs, and others to be discovered, are promising 
therapeutic targets and could be the road to finally 
overcoming treatment resistant aggressive prostate cancer. 
More research is needed for the whole interaction map to 
come into picture and be able to target individual 
microRNAs in an individualized course of treatment.  
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